ALCAM Molekülinformation
Molecule Name
Activated leukocyte cell adhesion molecule
Molekülalias
CD166,ALCAM,CD6L,KG-CAM,MEMD
Drug Development Progress
Anzahl der klinischen Arzneimittel1
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
CD166 antigen，Activated leukocyte cell adhesion molecule，CD166，ALCAM，MEMD，Activated Leucocyte Cell Adhesion Molecule，Activated-Leukocyte Cell Adhesion Molecule
Molekülhintergrund
CD166 antigen is a 100-105 kD typeI transmembrane glycoprotein that is a member of the immunoglobulin superfamily of proteins, which is also known as Activated leukocyte cell adhesion molecule (ALCAM) in human, SC-1/DM-GRASP/BEN in the chicken, and KG-CAM in the rat. CD166 is a cell adhesion molecule that binds to CD6. CD166 involved in neurite extension by neurons via heterophilic and homophilic interactions.
ALCAM Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Praluzatamab ravtansine | CX-2009 | Phase 2 Clinical | Cytomx Therapeutics Inc, Immunogen Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |